Antihistamine (H1, second-generation)

Acrivastine

Brand names: Benadryl Allergy Relief

Acrivastine is a non-sedating second-generation H1 antihistamine used for the symptomatic relief of allergic rhinitis and urticaria.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively blocks peripheral histamine H1 receptors, antagonising the effects of histamine released during allergic responses.

Prescribing in practice

Although classed as non-sedating, it can still cause drowsiness in some patients, who should be cautioned about driving or operating machinery until its effects are known.
It is renally excreted, so caution and dose review are advised in significant renal impairment.
Short duration of action means it is typically taken several times daily rather than once daily.

Monitoring

Routine laboratory monitoring is not required; assess symptom control and tolerability clinically.

Counselling the patient

Take to relieve symptoms and report if drowsiness occurs.
Avoid alcohol, which may add to any sedative effect.
Seek advice if symptoms persist despite regular use.

Evidence & guidelines

Second-generation antihistamines are recommended by NICE as first-line pharmacological treatment for allergic rhinitis.

Reference: SmPC Benadryl Allergy Relief; BSACI Rhinitis Guideline 2017; NICE CKS Allergic Rhinitis; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways